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The tumor suppressor miR‑642a‑5p 
targets Wilms Tumor 1 gene 
and cell‑cycle progression 
in prostate cancer
Dianne J. Beveridge1,2,5, Kirsty L. Richardson1,2,5, Michael R. Epis1,2,5, Rikki A. M. Brown1,2, 
Lisa M. Stuart1,2, Andrew J. Woo1,2,3 & Peter J. Leedman1,2,4*
RNA‑based therapeutics are emerging as innovative options for cancer treatment, with microRNAs 
being attractive targets for therapy development. We previously implicated microRNA‑642a‑5p 
(miR‑642a‑5p) as a tumor suppressor in prostate cancer (PCa), and here we characterize its mode of 
action, using 22Rv1 PCa cells. In an in vivo xenograft tumor model, miR‑642a‑5p induced a significant 
decrease in tumor growth, compared to negative control. Using RNA‑Sequencing, we identified 
gene targets of miR‑642a‑5p which were enriched for gene sets controlling cell cycle; downregulated 
genes included Wilms Tumor 1 gene (WT1), NUAK1, RASSF3 and SKP2; and upregulated genes 
included IGFBP3 and GPS2. Analysis of PCa patient datasets showed a higher expression of WT1, 
NUAK1, RASSF3 and SKP2; and a lower expression of GPS2 and IGFBP3 in PCa tissue compared to 
non‑malignant prostate tissue. We confirmed the prostatic oncogene WT1, as a direct target of miR‑
642a‑5p, and treatment of 22Rv1 and LNCaP PCa cells with WT1 siRNA or a small molecule inhibitor 
of WT1 reduced cell proliferation. Taken together, these data provide insight into the molecular 
mechanisms by which miR‑642a‑5p acts as a tumor suppressor in PCa, an effect partially mediated by 




PCa  Prostate cancer
RNA-Seq  RNA-sequencing
3′UTR  3′Untranslated region
siRNA  Small interfering RNA
RT-qPCR  Reverse transcription and quantitative polymerase chain reaction
DOHH  Deoxyhypusine hydroxylase
WT1  Wilms Tumor 1 gene
NUAK1  NUAK family SNF1-like kinase 1
RASSF3  Ras association domain family member 3
SKP2  S-phase kinase-associated protein 2
GPS2  G Protein Pathway Suppressor 2
IGFBP3  Insulin-like growth factor-binding protein 3
17-AAG  17-(Allylamino)-17-demethoxygeldanamycin (Tanespimycin)
Prostate cancer (PCa) is the second most diagnosed cancer worldwide accounting for 3.8% of cancer related death 
in  men1. PCa diagnoses have increased in recent years, which is attributable to both the broader awareness of 
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the disease, improved detection methods, and the emergence of screening for biomarkers (e.g. Prostate-Specific 
Antigen (PSA))2. There has also been a significant increase in the early diagnosis of localized, low-risk PCa, rang-
ing from 10 to 80% of all men diagnosed with PCa  worldwide3, with a subsequent decrease in PCa  mortality4. A 
sizeable proportion of men with low-risk PCa are carefully monitored via active surveillance and do not require 
treatment or  surgery5,6. PCa growth is initially androgen-dependant via the expression of the androgen receptor 
(AR), providing the basis for androgen deprivation therapies. In the last decade, the development of multiple 
drugs that target the androgen axis has improved the survival of PCa patients, including Abiraterone Acetate 
and  Enzalutamide7–9. Unfortunately in many men, the disease transforms into hormone refractory or castrate 
resistant prostate cancer (CRPC), whereby tumors become increasingly resistant to conventional AR pathway 
inhibitor treatments characterized by metastasis and premature  death10,11. Thus, there remains a large unmet 
clinical need to develop novel approaches to treat PCa, especially advanced CRPC.
MicroRNAs (miRNAs) are a family of ~ 22 nucleotide noncoding RNAs that are powerful regulators of gene 
expression via targeting of the 3′untranslated region (3′UTR) of specific genes leading to translational repression 
or message  decay12. With their aberrant expression known to play a pivotal role in the regulation of a variety 
of developmental processes and diseases, miRNAs have therapeutic potential for the treatment of cancer and 
other  illnesses13. Several miRNA-targeted therapies have reached clinical development, including miR-34 (in 
the form of a double-stranded miRNA mimic) for treating cancer, and miR-122 (in the form of antimiRs) for 
treating hepatitis  C14,15. There is aberrant miRNA expression in cancer, leading to both inhibition and promotion 
of the tumorigenic process, with respective loss of expression of tumor suppressor miRNAs or overexpression of 
oncogenic miRNAs (oncomiRs)16–18. In PCa, there has been the identification of miRNA signatures associated 
with either poor prognosis or response to therapy, and some have potential functional roles as  biomarkers19–24. 
These studies emphasize the potential for miRNAs to become cancer therapeutics, and provides an opportunity 
to identify downregulated tumor suppressor miRNAs, the replacement of which could be a new strategy in the 
treatment of PCa.
Previously, we discovered that miR-642a-5p is a tumor suppressor in  PCa25. We showed overexpression of 
miR-642a-5p in PCa cells resulted in reduced cell viability, and deoxyhypusine hydroxylase (DOHH) to be a 
direct target of miR-642a-5p. DOHH catalyzes the activation of eukaryotic translation initiation factor (eIF5A), 
a protein essential for cell growth, and therefore the targeting of DOHH by miR-642a-5p resulted in less eIF5A 
activity and a reduction in cell proliferation. Additionally, we found miR-642a-5p to be downregulated in PCa 
cell lines or tissue, relative to matched normal cells or tissue, the expression of which was not attributable to the 
hyper methylation of its  promoter25.
Here, we investigated the mode of action of miR-642a-5p in PCa, and aimed to identify novel downstream 
targets of miR-642a-5p, to further understand its effect as a tumor suppressor and potential as a prospective PCa 
therapeutic. In an in vivo xenograft model of PCa, transient overexpression of miR-642a-5p potently reduced 
tumor growth. RNA-Sequencing (RNA-Seq) analysis of miR-642a-5p treated PCa cells identified dysregulation 
of genes that cluster to specific pathways including cancer, cell cycle, organismal injury and abnormalities, and 
cellular growth and proliferation. Further, we identified for the first time Wilms Tumor 1 gene (WT1), which is 
an oncogene in  PCa26,27, as a new direct target of miR-642a-5p in PCa, providing novel insight into the role of 
miR-642a-5p as a tumor suppressor in PCa. Taken together, in PCa, miR-642a-5p has broad anti-tumor activity 
acting on several tumor pathways, and specifically on genes that regulate proliferation and cell cycle progression.
Results
miR‑642a‑5p inhibits prostate cancer xenograft tumor growth and increases survival. In order 
to investigate the effect of miR-642a-5p on PCa cell growth in vivo, we transiently overexpressed miR-642a-5p or 
a negative control miRNA (miR-NC) in human 22Rv1 PCa cells (representative of castrate resistant  disease28), 
and subcutaneously transplanted them into male NOD/SCID gamma (NSG) mice to generate xenografts (10 
mice/group). Subsequent to day 25-post injection, we observed a rapid increase in xenograft tumor volume in 
the miR-NC mice compared to the miR-642a-5p mice (Fig. 1a). Coronal and axial magnetic resonance imag-
ing (MRI) of animals at 34  days post injection also corroborated the differences in tumor volume observed 
between the two groups (Fig. 1b). The end point based on tumor size (1500  mm3) was reached first by mice in 
the miR-NC transfected group at day 34 post injection, and all miR-NC xenografts reached end point by day 41 
(Fig. 1c). In contrast, only one of the 10 mice in the miR-642a-5p group reached end point at day 41, with the 
remainder of the mice in this group progressively reaching end point by day 49 (Fig. 1c). The tumor size-based 
survival of the miR-642a-5p treated mice was significantly different to the miR-NC treated mice, as determined 
by Log-rank (Mantel-Cox) and Gehan–Breslow–Wilcoxon analyses (p < 0.0001; p < 0.0002, respectively). Taken 
together, these data indicate that transient overexpression of miR-642a-5p significantly inhibits PCa xenograft 
growth and is associated with increased survival.
RNA‑Sequencing target gene identification and pathway analysis. To explore the mechanism of 
miR-642a-5p’s potent inhibition of 22Rv1 PCa xenograft growth, we performed RNA-Seq analysis of 22Rv1 cells 
treated with miR-642a-5p or miR-NC (30 nM for 24 h). Using ≥ 0.5  log2 fold change and p < 0.05, we identified 
448 genes that were differentially expressed between the two groups; 176 genes were downregulated and 272 
were upregulated (Fig. 2a and Supplementary Tables S1 and S2). Of the 176 genes that were downregulated by 
miR-642a-5p overexpression, 72 (~ 41%) contained at least one miR-642a-5p seed site (via TargetScan 7.2), and 
these genes are listed in Supplementary Table S3. DOHH, which we previously identified as a direct target of 
miR-642a-5p, was ranked at the top of Supplementary Table S3 having 6 seed sites and was downregulated 0.69 
 log2 fold (25 and Supplementary Table S3). Interestingly, of the 272 genes that were upregulated by miR-642a-5p 
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overexpression, 47 (~ 17%) also contained at least one miR-642a-5p seed site, and these genes are listed in Sup-
plementary Table S4 and are putative indirect targets of miR-642a-5p.
To ascertain the major gene networks and biological pathways regulated by miR-642a-5p in 22Rv1 cells, we 
performed Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) of the 448 differentially 
expressed genes from the RNA-Seq data. The GSEA analysis identified the KEGG (Kyoto Encyclopedia of Genes 
and Genomes)29 pathway ‘DNA replication’ as a significantly depleted gene network following miR-642a-5p 
overexpression (Fig. 2b). We identified cancer, cell cycle, organismal injury and abnormalities, and cellular 
growth and proliferation as the most significantly enriched biological processes (ranked by the p-value result of 
a Fisher’s exact test) with miR-642a-5p treatment (Fig. 2c).
Effect of miR‑642a‑5p on cell cycle progression. To further investigate the effect of miR-642a-5p on 
the cell cycle (Fig. 2c), we performed flow cytometry cell cycle analysis of 22Rv1 cells transfected with miR-
642a-5p or miR-NC, and found that miR-642a-5p induces cell cycle arrest at G0/G1 and a block in transition to 
S phase (Fig. 2d). We next overexpressed miR-642a-5p in 22Rv1 cells, and consistent with these cells harboring 
wild-type  p5330, we observed an increase in the expression of the tumor suppressor cell cycle inhibitors p53 
and p21, which supports the observed cell cycle arrest at G0/G1 (Fig. 2e). We then determined if miR-642a-5p 
overexpression affects apoptosis, and following annexin V, propidium iodide (PI) staining and flow cytometry, 
there was an increase in the apoptotic fraction of miR-642a-5p treated cells, however this difference was not 
statistically significant (p > 0.05) (Fig. 2f). Taken together, these data support the notion that mediation of the 
growth inhibitory action of miR-642a-5p in 22Rv1 PCa cells is, in part, via alteration of cell cycle progression.
Identification of genes regulated by miR‑642a‑5p and implicated in cell cycle arrest. Further 
interrogation of the RNA-Seq data by IPA revealed a number of novel putative cell cycle associated gene tar-
gets for miR-642a-5p, which were either significantly (p < 0.05) downregulated or upregulated ≥ 0.5  log2 fold. 
Downregulated genes included WT1, NUAK1 [NUAK family SNF1-like kinase 1; also known as AMPK-related 
protein kinase 5 (ARK5)], RASSF3 (Ras association domain family member 3), and SKP2 (S-phase kinase-
associated protein 2), and are indicated in green in Fig. 3a. Conversely, GPS2 (G Protein Pathway Suppressor 
2; also known as AMF1) and IGFBP3 (Insulin-like growth factor-binding protein 3) indicated in red in Fig. 3a 
were upregulated by miR-642a-5p in the RNA-Seq and are all associated with G0/G1 arrest (IPA). We further 
validated these findings by transiently overexpressing miR-642a-5p or miR-NC in 22Rv1 cells and measured the 











































Figure 1.  miR-642a-5p inhibits PCa xenograft tumor growth and increases survival. Subcutaneous xenograft 
study of 22Rv1 PCa cells transiently overexpressing miR-642a-5p or miR-NC in NSG mice (10 per group). (a) 
Xenograft tumor volumes in mice measurable from day 25 to day 34. CI = 0.95; ***p < 0.0002. (b) Coronal and 
axial MRI images of day 34 representative mice from both miR-NC and miR-642a-5p xenograft groups. Red 
arrows indicate tumor. (c) Tumor size end point Kaplan–Meier survival curve of miR-642a-5p versus miR-NC 
xenograft mice. Log-rank (Mantel-Cox) Test ***p < 0.0001, Gehan–Breslow–Wilcoxon Test ***p < 0.0002.
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Figure 2.  miR-642a-5p targets genes and pathways involved in DNA replication and cell cycle arrest. (a) 
Volcano plot of RNA-Seq results, with green dots representing genes downregulated, and red dots representing 
genes upregulated (≥ 0.5  log2 fold change; p < 0.05) by miR-642a-5p. (b) Gene Set Enrichment Analysis (GSEA) 
of the RNA-Seq data. The y-axis and the green line show the enrichment score for each gene, illustrated as a 
vertical line plotted in rank order of the most gene abundance (red, left) to the least gene abundance (blue, right) 
within the indicated samples (as  log2FC/comparison); the black vertical lines correspond to member genes 
from the set. NES normalized enrichment score, FDR false discovery rate. (c) Ingenuity Pathway Analysis of 
the miR-642a-5p up and downregulated genes. Pathways ranked by the p value result of a Fisher’s exact test. (d) 
Flow cytometry cell cycle analysis of 22Rv1 cells transfected with miR-642a-5p or miR-NC (30 nM) for 72 h. 
n = 3; *p < 0.05, **p < 0.005 relative to miR-NC. (e) Western blot analysis of p21 and p53 protein expression 72 h 
post-transfection of 22Rv1 cells with 30 nM miR-642a-5p or miR-NC. β-actin is the loading control. Bands are 
from non-adjacent lanes of the same western blot and are separated by white space (see Supplementary Fig. S1A 
for uncropped blots, which were cut into smaller strips prior to immunoblotting). n = 3. (f) Flow cytometry 



























































































































































































































n=50 n=52 n=23 n=89n=29 n=131
c)
Figure 3.  Cell cycle arrest gene targets of miR-642a-5p. (a) Ingenuity Pathway Analysis of cell cycle targets 
of miR-642a-5p. Green denotes genes downregulated by miR-642a-5p, and the number of seed sites in their 
3’UTR (identified by TargetScan 7.2) indicated. Red denotes genes upregulated by miR-642a-5p. (b) RT-qPCR 
analysis of the cell cycle genes following overexpression of miR-642a-5p in 22Rv1 PCa cells. Expression of target 
mRNAs is normalized to HPRT housekeeping gene expression, calculated using the  2−ΔΔCt method, and relative 
to miR-NC. Error bars = SE; n = 3; *p < 0.05 relative to miR-NC. (c) Oncomine analysis of the expression of the 
miR-642a-5p targets in PCa data sets. (i) WT1; (ii) NUAK1; (iii) RASSF3; (iv) SKP2; (v) IGFBP3; and (vi) GPS2. 
The data cohorts indicated above each graph, and n per group shown. Boxes denote the median (horizontal 
line); whiskers indicate distances to the highest and lowest values [for NUAK1 and RASSF3 the lower whisker is 
to the 10th percentile (minimum value removed)]. *p < 0.05, **p < 0.005.
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regulated, and the expression of IGFBP3 was upregulated following miR-642a-5p treatment (Fig. 3b). There was 
no significant difference in GPS2 mRNA levels following miR-642a-5p overexpression (data not shown). Taken 
together, these data support the regulation of cell cycle genes as a key proposed mechanism of miR-642a-5p 
action in PCa cells.
Clinical impact of the miR‑642a‑5p cell cycle targets. To explore the potential clinical impact of 
these data we used Oncomine analysis to interrogate various PCa datasets and compared the gene expression of 
our miR-642a-5p targets between normal prostate and PCa samples. Examination of these cohorts revealed that 
each of the downregulated miR-642a-5p target genes (WT1, NUAK1, RASSF3, and SKP2) is a potential driver 
of tumor progression, as each of their expression levels was higher in prostate tumor samples when compared 
to normal prostate tissue (Fig. 3c i–iv). Conversely, both IGFBP3 and GPS2, which were upregulated with miR-
642a-5p overexpression in RNA-Seq, had lower levels of expression in the PCa samples (Fig. 3c v and vi). This 
data suggests that miR-642a-5p coordinately regulates (either up or down) a range of genes, with the net result 
of substantially decreasing PCa cell growth.
Validation of WT1 as a direct target of miR‑642a‑5p. There is increasing evidence suggesting that 
WT1 functions as an oncogene in  PCa26, and given its involvement in cell cycle  progression27, the existence of 
three miR-642a-5p seed sites within its 3′UTR (Fig. 4a and Supplementary Table S3), and its clinical impact 
[Fig. 3c(i)], we chose to evaluate WT1 further as a target of miR-642a-5p. To ascertain whether WT1 is a direct 
target of miR-642a-5p, we transiently co-transfected a luciferase reporter construct containing the first 1293 
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Figure 4.  WT1 is a direct target of miR-642a-5p in PCa cells. (a) The 3′UTR of WT1 has three putative miR-
642a-5p seed sites as predicted by TargetScan 7.2. (b) Schematic of the 3′UTR of WT1 (not to scale). Depiction 
of the GeneCopoeia target clone, which contains only the first 1293 base pairs of the 3′UTR, is with green 
shading. The grey shaded boxes indicate the miR-642a-5p seed sites. (c) Luciferase reporter gene analysis of the 
3′UTR of the putative miR-642a-5p target WT1 in 22Rv1 and LNCaP PCa cells transiently overexpressing miR-
642a-5p or miR-NC (20 nM). DOHH and miR-642a-5p perfect targets are positive controls. Error bars = SD; 
n = 3; **p < 0.005.
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22Rv1 and LNCaP PCa cells. Transfection of miR-642a-5p significantly (p < 0.005) downregulated the luciferase 
reporter activity of WT1 3′UTR in both of the PCa cell lines validating the direct targeting of miR-642a-5p 
(Fig. 4c). As positive controls, we included the DOHH 3′UTR construct, as well as a reporter containing the per-
fect target sequence for miR-642a-5p25. Together with the TargetScan prediction of three seed sites, this data is 
the first evidence supporting the concept that WT1 is a direct target of miR-642a-5p, and therefore an important 
downstream target of miR-642a-5p.
Targeted siRNA knockdown of WT1 reduces cell proliferation and blocks cell cycle progres‑
sion. We next used small interfering RNA (siRNA) to transiently knockdown WT1 gene expression in 22Rv1 
and LNCaP PCa cells, to assess the functional effects of WT1 on PCa growth. We initially tested four different 
WT1 siRNAs in 22Rv1 cells, and RT-qPCR quantitation confirmed an approximate 80% reduction in WT1 
expression with the ‘WT1#8’ siRNA, as compared to negative control siRNA (si-NC) (Supplementary Fig. S2A). 
We subsequently used WT1#8 siRNA in our experiments, and in each instance validated WT1 knockdown via 
RT-qPCR (Supplementary Fig.  S2B–E). We transiently transfected 22Rv1 and LNCaP cells with either WT1 
siRNA or si-NC and assessed cell proliferation using a Cell Titer end-point assay or the xCELLigence real time 
system. WT1 siRNA transfected cells exhibited a substantial growth reduction as compared to the si-NC trans-
fected cells using both methods of evaluation (Fig. 5a, b). Furthermore, siRNA-mediated knockdown of WT1 
reduced colony formation in clonogenicity assays (Fig. 5c). We also performed flow cytometry cell cycle analysis 
of 22Rv1 and LNCaP PCa cells transfected with WT1 siRNA or si-NC, and found that WT1 knockdown induced 
cell cycle arrest at G0/G1, and a concurrent increase in p21 and p53 expression (Fig. 5d, e). Additionally, treat-
ment of 22Rv1 and LNCaP PCa cells with a combination of both WT1 siRNA and a clinically available inhibitor 
of WT1 (Tanespimycin (17-AAG [17-(allylamino)-17-demethoxygeldanamycin]), resulted in a further reduc-
tion of cell growth than with WT1 siRNA or 17-AAG alone (Fig. 5f). Taken together, these data suggest that 
therapeutic targeting of WT1 in PCa could be beneficial for tumor growth inhibition.
Overexpression of WT1 increases colony formation and miR‑642a‑5p rescues this effect. To 
further investigate the anti-cancer contribution of WT1 targeting by miR-642a-5p, we transiently and stably 
overexpressed WT1 cDNA (WT1-203 isoform) in 22Rv1 and LNCaP PCa cells, and transfected these cells with 
30 nM miR-642a-5p or miR-NC. RT-qPCR analysis validated the stable or transient WT1 overexpression, and 
subsequent miR-642a-5p treatment significantly downregulated WT1 expression (Fig. 6a). Overexpression of 
WT1 in 22Rv1 PCa cells resulted in an increase in colony formation in clonogenicity assays, an effect which was 
rescued with miR-642a-5p overexpression (Fig. 6b). Taken together, miR-642a-5p replacement in 22Rv1 and 
LNCaP PCa cells with ectopic overexpression of WT1 significantly ‘rescues’ its anti-cancer effects on WT1 gene 
targeting, further suggesting miR-642a-5p could be an ideal therapy in PCa.
Discussion
There have been numerous reports regarding the molecular signatures and functions of specific microRNAs 
in cancer, and there are important opportunities to identify tumor suppressor  microRNAs15,31–33. There is little 
known about the functional role of miR-642a-5p and cancer, and here we characterize its mode of action as a 
tumor suppressor in 22Rv1 and LNCaP PCa cells, both being models of  CRPC34. Overexpression of miR-642a-5p 
resulted in a considerable decrease in xenograft tumor growth in vivo, and its overexpression dysregulated 
genes involved in DNA replication and cell cycle progression. Further, the expression of the cell-cycle-regulated 
genes which were either downregulated (e.g. WT1, NUAK1, RASSF3, and SKP2) or upregulated (e.g. GPS2 and 
IGFBP3) by miR-642a-5p in PCa were inversely related to the effect of the miRNA; those genes downregulated 
by miR-642a-5p were upregulated in tumor compared to normal prostate and vice versa, further supporting 
miR-642a-5p as a tumor suppressor microRNA. Additionally, our data suggest that direct therapeutic targeting 
of the miR-642a-5p cell cycle target genes, in particular WT1, could produce significant anti-tumor effects to 
benefit PCa patients.
We first described miR-642a-5p as a tumor suppressor in  PCa25, and indeed, there are few studies exploring 
the role of miR-642a-5p in cancer. In one report, expression of miR-642a-5p was downregulated in colon cancer 
cell lines and tumor tissue compared to normal, and overexpression of miR-642a-5p reduced the growth of colon 
cancer cell lines in vitro and in vivo35, further supporting our observations of miR-642a-5p as a tumor suppres-
sor. Interestingly, also in colon cancer, the long non-coding RNA LINC01234 and the circular RNA-103809 have 
been shown to act as competing endogenous RNAs (ceRNA) or ‘sponges’ of miR-642a-5p, thereby reducing its 
bioavailability and tumor suppressive  functions35,36. Additionally, the expression of miR-642a-5p was reduced in 
colorectal cancer cells, in peripheral immune cells following resection of lung tumors, and in childhood hema-
tological cancers suggesting a potential biomarker role of miR-642a-5p in the diagnosis of these  cancers37–39. 
Another recent report demonstrated a tumor suppressive function of miR-642a in liver cancer (hepatocellular 
carcinoma (HCC)); miR-642a expression was decreased, which enabled increased SEMA4C expression and 
signaling via the p38 MAPK  pathway40. Also in HCC, Tang and colleagues showed miR-642 to be a tumor sup-
pressor ceRNA, via interacting with, and disrupting the oncogenic functions of Linc00974 and  KRT1941. In a 
study investigating advanced bladder cancer, expression of miR-642a-5p was reduced in patient tumors, and 
transient overexpression of miR-642a-5p mimics in bladder cancer cells in vitro reduced their viability, consist-
ent with a tumor suppressor  role42. Taken together, these studies provide increasing evidence that miR-642a-5p 
is a potent tumor suppressor across several cancer types.
Dysregulation of cell cycle and its control underpins cancer biogenesis and its capacity to  proliferate43. Our 
data demonstrate that miR-642a-5p overexpression regulates a coordinated set of genes that drive cell cycle arrest 
at the G0/G1 (proliferation or quiescence) phase, and support cell cycle arrest as a proposed key mechanism of 
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Figure 5.  Targeted siRNA-mediated inhibition of WT1 expression reduces PCa cell proliferation and blocks cell 
cycle progression. (a) Relative cell viability of 22Rv and LNCaP PCa cells measured via cell titer assay at 3 d post-
transfection with WT1 siRNA or si-NC (20 nM). Validation of WT1 knockdown see Fig. S2B. Error bars = SD; n = 3; 
**p < 0.005. (b) Proliferation of 22Rv1 and LNCaP PCa cells (cell index) measured using the xCELLigence system post 
WT1 siRNA or si-NC transfection (20 nM). Validation of WT1 knockdown see Fig. S2C. Error bars = SD; n = 3. (c) 
Colony formation assay of 22Rv1 and LNCaP PCa cells 14–21 days post WT1 siRNA or si-NC (20 nM) transfection. 
Validation of WT1 knockdown see Fig. S2C. Error bars = SD; n = 3; **p < 0.005. (d) Flow cytometry cell cycle analysis of 
22Rv1 and LNCaP PCa cells transfected with WT1 siRNA or si-NC (20 nM) for 72 h. Validation of WT1 knockdown 
see Fig. S1D. n = 3; *p < 0.05, **p < 0.005 relative to si-NC. (e) Western blot analysis of p21 (22Rv1 and LNCaP) and p53 
(22Rv1) protein expression 72 h post-transfection of PCa cells with 20 nM WT1 siRNA or si-NC. β-actin is the loading 
control. Validation of WT1 knockdown see Fig. S2E. For full-length, non-cropped blots see Fig. S1B and S1C. n = 3. (f) 
Relative cell viability of 22Rv1 and LNCaP PCa cells measured via cell titer assay at 5 days post-transfection with WT1 
siRNA or si-NC (20 nM), and 3 d post-17-AAG treatment (1 µM). Validation of WT1 knockdown see Fig. S2B. Error 
bars = SD; n = 3; **p < 0.005.
9
Vol.:(0123456789)
Scientific Reports |        (2021) 11:18003  | https://doi.org/10.1038/s41598-021-97190-x
www.nature.com/scientificreports/
miR-642a-5p action. Cyclin-dependent kinases (CDKs) are critical enzymes that promote transition through 
the cell cycle and hence the targeting of these in proliferating cancer cells has been the basis for development 
and clinical application of novel anticancer  therapies43–45. The CDK inhibitors p21 and p53 are known tumor 
suppressors and play key roles in regulating transition of cells through the cell  cycle46. Our data showing their 
upregulation following miR-642a-5p overexpression also support the role of miR-642a-5p as a tumor suppres-
sor in PCa. Interestingly, miR-642a-5p’s ability to reduce cell viability of PCa cells is not reliant on cellular p53 
status, as our previous study using other PCa cell subtypes which harbour non-functional p53 (e.g. DU145) also 
showed a reduction in cell viability with miR-642a-5p  overexpression25,30.
Wilms Tumor 1 (WT1) gene is a member of the early growth response gene I (EGR-1) family of zinc finger 
transcription factors, having an important role in the normal development of the genitourinary system and other 
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Figure 6.  WT1 overexpression increases colony formation and miR-642a-5p rescues this effect. (a) RT-qPCR 
analysis of WT1 gene expression following stable or transient LeGO-iT2-WT1-203 or LeGO-iT2-Empty 
plasmids, and overexpression of miR-642a-5p or miR-NC in 22Rv1 and LNCaP PCa cells. Expression of WT1 is 
normalized to HPRT housekeeping gene expression, calculated using the  2−ΔΔCt method, and relative to Empty 
vector + miR-NC. Error bars = SE; n = 3; *p < 0.05, **p < 0.005 relative to Empty vector + miR-NC. #p < 0.05 WT1-
203 + miR-NC relative to WT1-203 + miR-642a-5p. (b) Colony formation assay of 22Rv1 PCa cells 14 days post 
transient WT1 overexpression/empty vector transfection and miR-NC/miR-642a-5p (30 nM) co-transfection. 
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organs and  tissues47,48. In addition to the requisite role of WT1 in development, it also plays a complex role in 
tumorigenesis, acting as either a tumor suppressor or an oncogene depending on the cellular  context47,48. There 
is mounting evidence that WT1 functions as an oncogene in PCa, acting by facilitating the development of a 
lethal metastatic  phenotype26,27. In addition, WT1 expression is elevated in high-grade PCa tissues, and the level 
of expression may serve as a biomarker for PCa  progression49. Furthermore, administration of 17-AAG, a clini-
cally available inhibitor of WT1 (via its interaction with heat shock protein 90), was shown to decrease myeloid 
leukemia xenograft growth, correlating with decreased expression of WT1 and its downstream  targets50. Our 
data suggests WT1 is a direct target of miR-642a-5p, and siRNA or 17-AAG targeting of WT1 reduced cellular 
proliferation in 22Rv1 and LNCaP PCa cells. Furthermore, when WT1 was overexpressed in 22Rv1 and LNCaP 
cells miR-642a-5p overexpression effectively reduced WT1 gene expression and colony formation. These data, 
together with our TCGA Oncomine data, support the concept that therapies targeting WT1, such as miR-642a-5p 
replacement treatment or 17-AAG, could reduce PCa growth and potentially represent treatment alternatives.
The other putative miR-642a-5p target genes, which are associated with cell cycle, have roles as oncogenes 
or tumor suppressors in cancer. SKP2, which is overexpressed in  PCa51, plays a critical role in cancer develop-
ment by controlling several cellular processes such as cell cycle regulation and cell proliferation, by degrading 
specific CDK  inhibitors52,53. Overexpression of NUAK1 is associated with poor prognosis in many cancers, 
including colorectal, ovarian, and  lung54–56. There is growing evidence showing NUAK1 is a target of multiple 
miRNAs, whose expression is frequently decreased during cancer progression to metastatic  disease57. Addi-
tionally, NUAK1 is a positive regulator of cell cycle progression in breast cancer  cells58. Our data supports the 
oncogenic function of SKP2 and NUAK1 in PCa, as their targeted degradation by miR-642a-5p resulted in cell 
cycle arrest. Conversely, RASSF3 functions as a tumor suppressor through stabilization of p53 and regulation of 
apoptosis and G1-S cell cycle  arrest59, its downregulation increases malignant phenotypes of non-small cell lung 
 cancer60, and is, in part, responsible for resistance to mammary tumor development in Neu transgenic  mice61. 
These reports are contradictory to our observation of RASSF3 targeting by miR-642a-5p for inhibition of cell 
cycle progression in PCa, and coupled with the Oncomine TCGA data showing a higher level of RASSF3 in PCa 
tissue, suggests RASSF3 function may be dependent on cellular context. We found miR-642a-5p overexpression 
upregulated IGFBP3 and GPS2 expression. This data is consistent with previous reports; IGFBP3 overexpres-
sion has been shown to induce cell cycle arrest at G1 phase in breast  cancer62 and suppress metastasis in  PCa63, 
and GPS2 overexpression in osteocarcinoma was associated with cell cycle  arrest64. Taken together, these data 
provide strong support for miR-642a-5p functioning as a potent tumor suppressor in PCa, an effect mediated by 
a coordinated change in expression of multiple targets leading to significant impact on cell cycle. We have previ-
ously studied other microRNAs, including miR-7-5p65 and miR-331-3p24, and identified multiple coordinately 
regulated downstream targets and signaling pathways, with a net effect of potent tumor inhibition, similar to 
what we identified herein.
There is an urgent need for new therapies for men with advanced PCa. Our data suggests miR-642a-5p is 
a potent PCa tumor suppressor in vitro and in vivo and that its successful replacement into PCa tissue could 
represent a new avenue of therapy for this disease. This is particularly relevant given that the field of RNA-based 
therapeutics is undergoing rapid change. With the recent approval of multiple siRNA drugs by the U.S. Food 
and Drug Administration there is an increased interest in using double stranded RNAs, including miRNAs, as 
therapies to treat human  disease15,66,67. In that context, our data provides a foundation for further work to develop 
miR-642a-5p into an RNA-based PCa therapeutic.
Methods
All the experimental protocols were performed in accordance with institutional guidelines and regulations of 
the Harry Perkins Institute of Medical Research.
Cell culture, miRNA precursors, luciferase reporter constucts, siRNA molecules, small mol‑
ecule inhibitors and cDNA expression constructs. 22Rv1 and LNCaP PCa cells were obtained from 
the American Type Culture Collection (ATCC) and cultured at 37  °C/5%  CO2 in RPMI-1640 supplemented 
with 10% fetal bovine serum (FBS). Synthetic miRNA molecules corresponding to human miR-642a-5p (hsa-
miR-642a-5p; Cat #AM17100, Product ID: PM11477) and a negative control miRNA (miR-NC; Negative Con-
trol #1, Cat# AM17110) were sourced from Ambion (Thermo Fisher Scientific). The miRNA 3′UTR luciferase 
reporter constuct for WT1 (#Hmi T058379-MT06) was generated by GeneCopoeia (Rockville, MD). The miR-
642a-5p perfect target and DOHH 3′UTR reporter constructs were generated by GenScript, Inc (Piscataway), as 
 described25. Flexitube siRNAs to WT1 were from Qiagen (WT1#1 Cat#SI00008267; WT1#4 Cat#SI00008288; 
WT1#7 Cat#SI03056298; and WT1#8 Cat#SI03061331). The negative control siRNA (si-NC) was from Ambion 
(Cat#4390843). Tanespimycin (17-AAG) was from Selleckchem (Cat#S1141). Human WT1 cDNA (WT1-203, 
ENST00000379079.8, Ensembl) was synthesized (GenScript) and cloned into LeGO-iT2 lentiviral vector (a gift 
from Boris Fehse, Addgene plasmid # 27343).
PCa cell xenograft model and tumor imaging. 22Rv1 cells were transfected using Lipofectamine 2000 
(Thermo Fisher Scientific) with 50 nM miR-642a-5p or miR-NC. At 72 h post transfection cells were trypsinized, 
counted, and 1.5 ×  106 cells in 150 µL of a 1:1 dilution of RPMI-1640 and Matrigel (BD BioSciences) was injected 
subcutaneously into male NSG mice (Animal Resource Centre, Western Australia) (10 per group). Generation 
of T2 weighted coronal and axial MRI images of NSG mice were by a 3.0 T MRS 3000 preclinical MRI system at 
the Australian Cancer Research Foundation Cancer Imaging Facility at the Harry Perkins Institute of Medical 
Research, Perth, Australia. All the experimental protocols were approved by the Harry Perkins Institute of Medi-
cal Research animal ethics committee (AE048/2016). All methods used for animal experimentation were carried 
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out in accordance with the relevant guidelines and regulations of the Harry Perkins Institute of Medical Research 
Animal Ethics Committee. All animal work was carried out in compliance with the ARRIVE guidelines (http:// 
www. nc3rs. org. uk/ page. asp? id= 1357).
RNA‑Sequencing expression profiling and analysis. For the RNA-Seq study, triplicate wells of 22Rv1 
cells were transfected using Lipofectamine 2000 with 30 nM miR-642a-5p or miR-NC, and total RNA extracted 
from the samples 24 h post-transfection, using the Isolate II RNA kit (Bioline) according to the manufacturer’s 
instructions. The quantity and integrity of extracted RNA was determined using a 2100 Bioanalyzer (Agilent 
Technologies), before RNA-Seq analysis using the Illumina HiSeq 2500 at the Australian Genome Research 
Facility (AGRF; Victoria, Australia). Analysts at AGRF normalized the data with the R Bioconductor ‘EdgeR’ 
package (www. Bioco nduct or. org). Briefly, sequence counts were aligned to the genome, background corrected, 
 log2 transformed, annotated, and a fold change analysis performed to compare treatment groups.
TargetScan (Version 7.2: March 2018) provided metadata on genes downregulated by miR-642a-5p in the 
RNA-Seq experiment. Gene Set Enrichment Analysis (GSEA) of the RNA-Seq data was performed as previously 
 described68. The biological pathway targets of genes differentially expressed by miR-642a-5p were determined 
using Ingenuity Pathway Analysis (IPA, Ingenuity System, Inc. www. qiage nbioi nform atics. com/ produ cts/ ingen 
uity- pathw ay- analy sis). The RNA-Seq data is available in the Gene Expression Omnibus under Accession Num-
ber GSE160736.
Cell cycle analysis. 22Rv1 or LNCaP PCa cells were transfected as described above with 30 nM miRNA 
(miR-642a-5p or miR-NC), or 20 nM siRNA (WT1 siRNA or si-NC) molecules. Following treatment for 72 h, 
floating and adherent cells were collected, fixed with cold 100% ethanol and stored at 4  °C. Fixed cells were 
stained with Propidium Iodide (PI) staining solution (25 µg/ml PI and 0.25 µg/ml RNase A in PBS), and ana-
lysed using the BD Accuri C6 Flow Cytometer and FlowJo Software (version 7.6.5), and the Dean-Jett-Fox 
method for gating cells.
Annexin V‑FITC/PI apoptosis assay. 22Rv1 cells were transfected as described above with 30 nM miR-
642a-5p or miR-NC for 72 h, or treated with 10 µM Camptothecin (Cayman Chemical) for 24 h (positive control 
for apoptosis). Apoptosis was measured using the Annexin V-FITC Apoptois Detection Kit I (BD Biosciences, 
NSW, Australia), using the manufacturer’s instructions. No stain, single stain and camptothecin treated cells 
were used to set gating strategies to identify live, apoptotic and dead cell populations. Samples were analysed 
using the BD Accuri C6 Flow Cytometer and software.
Generation of 22Rv1 and LNCaP stably overexpressing WT1 cell lines. 22Rv1 and LNCaP PCa 
cell lines stably expressing WT1-203 cDNA were generated by lentiviral transduction as previously  described69,70. 
Briefly, 22Rv1 and LNCaP cells were infected with lentiviruses carrying LeGO-iT2-Empty or LeGO-iT2-
WT1-203 plasmids, and transduced cells stably expressing tdTomato fluorescent protein were isolated by flow 
cytometry (FACSCalibur, BD Biosciences). The ectopic expression of WT1 in the isolated cells was validated 
with RT-qPCR.
Transfection of miRNA precursors, siRNA molecules, cDNA overexpression constructs, and 
reporter gene assays. Parental 22Rv1 and LNCaP PCa cells, or 22Rv1 and LNCaP cells with stable expres-
sion of LeGO-iT2-WT1-203 or LeGO-iT2-Empty plasmids were seeded into 6-well plates or 10  cm diam-
eter dishes and transfected as described above with miRNA or siRNA molecules at a final concentration of 
10–30 nM. Cells were harvested 24 h post-transfection for RNA isolation and 3 days for protein extraction. For 
transient WT1 overexpression, 5 ng of LeGO-iT2-WT1-203 or LeGO-iT2-Empty plasmids were cotransfected 
with 10–30 nM miRNA molecules, and RNA and protein isolated at 2 and 3 days post-transfection, respectively.
For Luciferase reporter gene assays 22Rv1 and LNCaP cells were seeded into 6-well plates and co-transfected 
with 450 ng of firefly luciferase reporter plasmid DNA and 10 nM final concentration of either miR-642a-5p 
or miR-NC, using Lipofectamine 2000. After 48 h, lysates were assayed for firefly luciferase activity using the 
Luciferase Reporter Assay System (Promega) and a Fluostar OPTIMA microplate reader (BMG Labtech).
Cell proliferation and colony forming assays. Parental or WT1-overexpressing 22Rv1 and LNCaP 
PCa cells were transfected in 10 cm dishes with miRNA molecules, siRNAs, or cDNA plasmid constructs (as 
described above). One day post-transfection, the cells were trypsinized and plated into 96 well plates, xCEL-
Ligence E-plates at 5000 cells/well, or into 10 cm dishes at 5000 cells (22Rv1) or 10,000 cells (LNCaP)/dish. 
Proliferation was evaluated in the 96 well plates at 1–7 days post-seeding using a CellTiter 96  AQueous One Solu-
tion Cell Proliferation Assay (Promega) and the Fluostar OPTIMA microplate reader, according to the manufac-
turer’s instructions. Treatment with 17-AAG (1 µM) was 24 h post-seeding, and proliferation evaluated 1–7 days 
later using the same assay (Promega). The xCELLigence system (In Vitro Technologies) was used to measure the 
proliferation of cells in a real time setting for 72 h, according to the manufacturer’s instructions. The cells which 
were plated into the 10 cm dishes were assayed for colony formation after 2–3 weeks, using Crystal Violet stain-
ing as previously  described65.
RNA extraction, reverse transcription and quantitative polymerase chain reaction 
(RT‑qPCR). Total RNA was extracted from 22Rv1 and LNCaP PCa cells 24 h post-transfection with miR-
NAs or siRNAs, using TRIzol reagent as per the manufacturer’s instructions (Thermo Fisher Scientific). RNA 
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was quantitated using the NanoDrop One spectrophotometer and 800 ng RNA was reverse transcribed using 
a QuantiTect reverse transcription kit (Qiagen). Quantitative PCR was performed in a Rotor-Gene Q thermo-
cycler (Qiagen) using Bioline SensiMix (QT605-20) and validated QuantiTect primers (Qiagen) for HPRT1 
(Cat#QT00059066, housekeeping control), WT1 (Cat#QT00059003), NUAK1 (Cat#QT00097447), RASSF3 
(Cat#QT00051044), SKP2 (Cat#QT00006489), IGFBP3 (Cat#QT00072737), or GPS2 (Cat#QT00050715). For 
the WT1 overexpression experiments, the following primers from Sigma were used: WT1-exon8 (F) GTG ACT 
TCA AGG ACT GTG AACG; and WT1-exon9 (R) CGG GAG AAC TTT CGC TGA CAA.
Expression of target mRNAs relative to HPRT expression was calculated using the  2−ΔΔCt  method71.
Protein extraction and western blotting. Protein extracts were prepared from cells lysed with mid-
RIPA buffer and western blotting performed as  described24. Briefly, protein samples were resolved in NuPAGE 
4–12% Bis Tris gels (Thermo Fisher Scientific) and transferred to PVDF membranes (Roche). Membranes were 
blocked in Tris-buffered saline/Tween 20 (TBST)/5% skim milk and incubated with p21 (Cell signaling #2947S; 
1:1000), p53 (Cell signaling #9282S; 1:500, or Santa Cruz #SC-126; 1:1000), or β-actin [AC-15] (Abcam ab6276; 
1:5000) primary antibodies, followed by incubation with horseradish peroxidase (HRP) linked secondary anti-
bodies [anti-mouse IgG (GE Healthcare; Cat#NA931V) or anti-rabbit IgG (GE Healthcare; Cat#NA934V)]. Pro-
tein detection was with enhanced chemiluminescence (ECL) using Luminata Classico Western HRP substrate 
(Millipore #WBLUC0100), and visualization was with either ECL-Hyperfilm (GE Healthcare; #GE HE28-9068-
37) or the iBright Imaging System (Thermo Fisher Scientific).
Clinical datasets. Oncomine (www. oncom ine. org) analyses determined the differential expression levels of 
WT1, NUAK1, RASSF3, SKP2, IGFBP3, and GPS2 between normal and tumor prostate tissue cohorts from The 
Cancer Genome Atlas (TCGA), Tomlins, Taylors Prostate 3 or Yu Prostate data sets.
Statistical analysis. Graphing and analysis of data was with GraphPad Prism 8 software. Use of the 
unpaired t-test (two-tailed) determined significant differences between clinical datasets in Oncomine, luciferase 
reporter assays, RT-qPCR assays, cell cycle analysis and apoptosis. Use of a two way ANOVA with repeated 
measures determined significant differences between PCa xenograft volumes. Log-rank (Mantel-Cox) and 
Gehan-Breslow-Wilcoxon testing was used for determining significant differences between xenograft survival 
curves. IPA molecular pathway analysis package used a Fisher’s exact test on genes identified by RNA-Seq.
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